Simple Blood-based Cancer Tests Show Early Promise Simple Blood-based Cancer Tests Show Early Promise

Patients with breast cancer or brain tumours could soon be diagnosed at a much earlier stage and potentially achieve better treatment outcomes if the promise of two UK studies holds true.Medscape News UK
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Related Links:

ConclusionAlthoughmost brain tumors are metastases, primary brain tumors should be considered a possibility even in the presence of another source of metastases; especially if there is a lesion refractory to treatment.
Source: Interdisciplinary Neurosurgery - Category: Neurosurgery Source Type: research
AbstractToday, bio-medical efforts are entering the subcellular level, which is witnessed with the fast-developing fields of nanomedicine, nanodiagnostics and nanotherapy in conjunction with the implementation of nanoparticles for disease prevention, diagnosis, therapy and follow-up. Nanoparticles or nanocontainers offer advantages including high sensitivity, lower toxicity and improved safety —characteristics that are especially valued in the oncology field. Cancer cells develop and proliferate in complex microenvironments leading to heterogeneous diseases, often with a fatal outcome for the patient. Although antibo...
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 1 November 2019Source: Journal of Molecular BiologyAuthor(s): Vincenzo Alterio, Markus Kellner, Davide Esposito, Friederike Liesche-Starnecker, Silvia Bua, Claudiu T. Supuran, Simona Maria Monti, Reinhard Zeidler, Giuseppina De SimoneAbstract6A10 is a CA XII inhibitory monoclonal antibody, which was demonstrated to reduce the growth of cancer cells in vitro and in a xenograft model of lung cancer. It was also shown to enhance chemosensitivity of multiresistent cancer cell lines, and to significantly reduce the number of lung metastases in combination with doxorubicin in mice carrying huma...
Source: Journal of Molecular Biology - Category: Molecular Biology Source Type: research
How can you have a moonshot trying to cure cancer and not mention people dying of cancer?I believed the narrative that is pushed on women, that if you check your breasts and if you catch it early, you’re fine.ide class="right-rail__container right-rail__container--ad"> Lianne Kraemer had been living with metastatic breast cancer for more than a year when I met her in December 2017 at the Henry B. González Convention Center in San Antonio. Throughout the week, more than 7,000 doctors, scientists and pharmaceutical-company representatives would descend on the city for the country’s most impor...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Breast Cancer health Source Type: news
AbstractBackgroundImmune therapies targeting the programmed cell death receptor (ligand) 1 (PD-1/PD-L1) axis have shown remarkable activity in a variety of solid tumors. While substantial responses were observed in asymptomatic patients with brain metastases (BM), their clinical activity in primary brain tumors remains limited. In a cohort of adult brain tumor patients, we aimed to analyze soluble PD-L1 (sPD-L1) levels in patient plasma as a systemic marker of tumor - immune system interactions.MethodsWe obtained EDTA plasma from 55 glioblastoma, 26 lower-grade (WHO grade II - III) glioma (LGG), 17 meningioma and 43 BM pat...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundSacituzumab govitecan (SG) is an antibody drug conjugate (ADC) that targets Trop-2 for the selective delivery of SN-38 to tumors. SG carries SN-38, a topoisomerase inhibitor active in the nanomolar range for most cells (including TNBC and GBM) and freely cross the blood brain barrier. SN-38 is conjugated to SG by a linker designated CL2A which is sensitive to acidic and conditions. SG was evaluated in a single-arm, multicenter trial with relapsed/refractory metastatic triple negative breast cancer (TNBC) with impressive results including a confirmed objective response rate of 30%, with responses occurring...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Host Kevin Patton summarizes many strategies from learning science that can amplify learning in our courses. Also, updates in the role of exosomes in the spread of cancer and how activity type affects the shape of our heart.00:48 | Jargon: Show Notes&Episode Pages05:07 | Sponsored by HAPS07:01 | Role of Exosomes in Spread of Cancer13:20 | Sponsored by AAA13:44 | Activity Type Affects Heart Shape18:03 | Sponsored by HAPI Online Graduate Program18:35 | Amplifying Learning in A&P: ANSWER53:30 | Staying ConnectedIf you cannot see or activate the audio playerclick here. Questions&Feedback:1-833-LION-...
Source: The A and P Professor - Category: Physiology Authors: Source Type: blogs
miR‑378a‑3p inhibits cellular proliferation and migration in glioblastoma multiforme by targeting tetraspanin 17. Oncol Rep. 2019 Aug 20;: Authors: Guo XB, Zhang XC, Chen P, Ma LM, Shen ZQ Abstract Glioblastoma multiforme (GBM) is the most common and aggressive brain tumor and patients with this disease tend to have poor clinical outcome. MicroRNAs (miRs) are important regulators of a number of key pathways implicated in tumor pathogenesis. Recently, the expression of miR‑378 was shown to be dysregulated in several different types of cancer, including gastric cancer, colorectal cancer and oral ca...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
FINDINGSCancer that has spread to the central nervous system is notoriously difficult to treat. Now, UCLA researchers have developed a drug delivery system that breaks through the blood-brain barrier in order to reach and treat cancer that has spread to the central nervous system.In research conducted in mice, a single dose of cancer drugs in a nanoscale capsule developed by the scientists eliminated all B-cell lymphoma that had metastasized to the animals ’ central nervous system.BACKGROUNDAbout 15% to 40% of all cancers spread to the nervous system, but there are few treatment options and they only work in a small ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Authors: Cao X, Xu J Abstract Inflammation has long been proven to engage in tumor initiation and progression. Inflammasome, as a member of innate immunity-induced host defense inflammation, also plays critical roles in cancer. Inflammasome is a multiprotein complex responding to pathogen-associated molecular patterns and damage-associated molecular patterns. It is composed of receptors such as NOD-like receptors and AIM2-like receptors, adaptor protein ASC, and effector caspase-1, which can process proinflammatory cytokines interleukin (IL)-1β and IL-18. It has been reported that upregulated inflammasome acti...
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Breast Cancer | Cancer | Cancer & Oncology | Health | Hematology | Neurology | Study